0 XP   0   0   0

Mega Lifesciences Public Company Limited










Financial Health of Mega Lifesciences Public Company Limited




Comparing to competitors in the Drug Manufacturers-Specialty & Generic industry




  Industry Rankings  


Mega Lifesciences Public Company Limited
Buy, Hold or Sell?

Should you buy, hold or sell Mega Lifesciences Public Company Limited?

I guess you are interested in Mega Lifesciences Public Company Limited. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

Let's analyse Mega Lifesciences Public Company Limited

Let's start. I'm going to help you getting a better view of Mega Lifesciences Public Company Limited. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

  1. Company's Financial Health
    A deep dive into the books. How are the numbers doing? Is Mega Lifesciences Public Company Limited even making a profit? Is the company skyrocketing? Or is it sinking like the Titanic. The trend is your friend.
  2. Market Valuation
    Finally, you now have an insight of how Mega Lifesciences Public Company Limited is doing in the market. If the company is worth buying. The latest step is to find out how other investors value Mega Lifesciences Public Company Limited. The closing price on 2022-12-08 was ฿45.25 per share. Is the company over- or underpriced?
  3. Key Performance Indicators
    A total overlook on how the company is doing. Based on the (trends in) the key performance indicators.
Mega Lifesciences Public Company Limited Daily Candlestick Chart

Summary

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is less efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating efficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

1.1. Profitability of Mega Lifesciences Public Company Limited.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Mega Lifesciences Public Company Limited earns for each ฿1 of revenue.

  • Above 10% is considered healthy but always compare Mega Lifesciences Public Company Limited to the Drug Manufacturers-Specialty & Generic industry mean.
  • A Net Profit Margin of 14.5% means that ฿0.14 for each ฿1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Mega Lifesciences Public Company Limited:

  • The MRQ is 14.5%. The company is making a huge profit. +2
  • The TTM is 15.3%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ14.5%TTM15.3%-0.8%
TTM15.3%YOY10.8%+4.4%
TTM15.3%5Y12.2%+3.1%
5Y12.2%10Y12.2%0.0%
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ14.5%0.4%+14.1%
TTM15.3%0.3%+15.0%
YOY10.8%0.2%+10.6%
5Y12.2%-0.7%+12.9%
10Y12.2%-0.1%+12.3%
1.1.2. Return on Assets

Shows how efficient Mega Lifesciences Public Company Limited is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Mega Lifesciences Public Company Limited to the Drug Manufacturers-Specialty & Generic industry mean.
  • 3.9% Return on Assets means that Mega Lifesciences Public Company Limited generated ฿0.04 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Mega Lifesciences Public Company Limited:

  • The MRQ is 3.9%. Using its assets, the company is less efficient in making profit.
  • The TTM is 4.3%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ3.9%TTM4.3%-0.3%
TTM4.3%YOY3.2%+1.1%
TTM4.3%5Y3.4%+0.9%
5Y3.4%10Y3.4%0.0%
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ3.9%0.1%+3.8%
TTM4.3%0.1%+4.2%
YOY3.2%-0.1%+3.3%
5Y3.4%-0.2%+3.6%
10Y3.4%0.1%+3.3%
1.1.3. Return on Equity

Shows how efficient Mega Lifesciences Public Company Limited is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Mega Lifesciences Public Company Limited to the Drug Manufacturers-Specialty & Generic industry mean.
  • 6.7% Return on Equity means Mega Lifesciences Public Company Limited generated ฿0.07 for each ฿1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Mega Lifesciences Public Company Limited:

  • The MRQ is 6.7%. Using its investors money, the company is less efficient in making profit.
  • The TTM is 7.1%. Using its investors money, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ6.7%TTM7.1%-0.4%
TTM7.1%YOY5.3%+1.8%
TTM7.1%5Y5.7%+1.3%
5Y5.7%10Y5.7%0.0%
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ6.7%0.6%+6.1%
TTM7.1%0.4%+6.7%
YOY5.3%0.4%+4.9%
5Y5.7%-0.3%+6.0%
10Y5.7%0.1%+5.6%

1.2. Operating Efficiency of Mega Lifesciences Public Company Limited.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Mega Lifesciences Public Company Limited is operating .

  • Measures how much profit Mega Lifesciences Public Company Limited makes for each ฿1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Mega Lifesciences Public Company Limited to the Drug Manufacturers-Specialty & Generic industry mean.
  • An Operating Margin of 15.3% means the company generated ฿0.15  for each ฿1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Mega Lifesciences Public Company Limited:

  • The MRQ is 15.3%. The company is operating efficient. +1
  • The TTM is 16.8%. The company is operating efficient. +1
Trends
Current periodCompared to+/- 
MRQ15.3%TTM16.8%-1.5%
TTM16.8%YOY10.4%+6.3%
TTM16.8%5Y14.2%+2.6%
5Y14.2%10Y14.2%0.0%
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ15.3%2.5%+12.8%
TTM16.8%1.6%+15.2%
YOY10.4%2.7%+7.7%
5Y14.2%1.8%+12.4%
10Y14.2%0.8%+13.4%
1.2.2. Operating Ratio

Measures how efficient Mega Lifesciences Public Company Limited is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers-Specialty & Generic industry mean).
  • An Operation Ratio of 1.42 means that the operating costs are ฿1.42 for each ฿1 in net sales.

Let's take a look of the Operating Ratio trends of Mega Lifesciences Public Company Limited:

  • The MRQ is 1.424. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.400. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.424TTM1.400+0.024
TTM1.400YOY1.465-0.065
TTM1.4005Y1.448-0.048
5Y1.44810Y1.4480.000
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ1.4241.473-0.049
TTM1.4001.456-0.056
YOY1.4651.398+0.067
5Y1.4481.374+0.074
10Y1.4481.191+0.257

1.3. Liquidity of Mega Lifesciences Public Company Limited.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Mega Lifesciences Public Company Limited is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers-Specialty & Generic industry mean).
  • A Current Ratio of 1.85 means the company has ฿1.85 in assets for each ฿1 in short-term debts.

Let's take a look of the Current Ratio trends of Mega Lifesciences Public Company Limited:

  • The MRQ is 1.850. The company is able to pay all its short-term debts. +1
  • The TTM is 1.921. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.850TTM1.921-0.072
TTM1.921YOY1.803+0.118
TTM1.9215Y1.784+0.137
5Y1.78410Y1.7840.000
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ1.8501.880-0.030
TTM1.9211.901+0.020
YOY1.8032.112-0.309
5Y1.7842.182-0.398
10Y1.7841.891-0.107
1.3.2. Quick Ratio

Measures if Mega Lifesciences Public Company Limited is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Mega Lifesciences Public Company Limited to the Drug Manufacturers-Specialty & Generic industry mean.
  • A Quick Ratio of 0.75 means the company can pay off ฿0.75 for each ฿1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Mega Lifesciences Public Company Limited:

  • The MRQ is 0.755. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.713. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.755TTM0.713+0.041
TTM0.713YOY0.657+0.056
TTM0.7135Y0.683+0.030
5Y0.68310Y0.6830.000
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7550.733+0.022
TTM0.7130.796-0.083
YOY0.6570.808-0.151
5Y0.6830.834-0.151
10Y0.6830.821-0.138

1.4. Solvency of Mega Lifesciences Public Company Limited.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Mega Lifesciences Public Company Limited assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Mega Lifesciences Public Company Limited to Drug Manufacturers-Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.41 means that Mega Lifesciences Public Company Limited assets are financed with 41.3% credit (debt) and the remaining percentage (100% - 41.3%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Mega Lifesciences Public Company Limited:

  • The MRQ is 0.413. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.395. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.413TTM0.395+0.018
TTM0.395YOY0.396-0.001
TTM0.3955Y0.408-0.014
5Y0.40810Y0.4080.000
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4130.437-0.024
TTM0.3950.424-0.029
YOY0.3960.398-0.002
5Y0.4080.398+0.010
10Y0.4080.401+0.007
1.4.2. Debt to Equity Ratio

Measures if Mega Lifesciences Public Company Limited is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Mega Lifesciences Public Company Limited to the Drug Manufacturers-Specialty & Generic industry mean.
  • A Debt to Equity ratio of 70.3% means that company has ฿0.70 debt for each ฿1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Mega Lifesciences Public Company Limited:

  • The MRQ is 0.703. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.655. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.703TTM0.655+0.048
TTM0.655YOY0.662-0.007
TTM0.6555Y0.695-0.040
5Y0.69510Y0.6950.000
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7030.652+0.051
TTM0.6550.675-0.020
YOY0.6620.623+0.039
5Y0.6950.684+0.011
10Y0.6950.697-0.002

2. Market Valuation of Mega Lifesciences Public Company Limited

2. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ฿1 in earnings Mega Lifesciences Public Company Limited generates.

  • Above 15 is considered overpriced but always compare Mega Lifesciences Public Company Limited to the Drug Manufacturers-Specialty & Generic industry mean.
  • A PE ratio of 0.00 means the investor is paying ฿0.00 for every ฿1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Mega Lifesciences Public Company Limited:

  • The EOD is 69.273. Neutral. Compare to industry.
  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
EOD69.273MRQ-+69.273
MRQ-TTM-0.000
TTM-YOY84.752-84.752
TTM-5Y21.188-21.188
5Y21.18810Y21.1880.000
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
EOD69.273-0.124+69.397
MRQ--0.437+0.437
TTM--0.102+0.102
YOY84.75215.340+69.412
5Y21.1887.916+13.272
10Y21.1887.700+13.488

2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Mega Lifesciences Public Company Limited is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers-Specialty & Generic industry mean).
  • A PB ratio of 0.00 means the investor is paying ฿0.00 for each ฿1 in book value.

Let's take a look of the Price to Book Ratio trends of Mega Lifesciences Public Company Limited:

  • The EOD is 4.643. Neutral. Compare to industry.
  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
EOD4.643MRQ-+4.643
MRQ-TTM-0.000
TTM-YOY4.419-4.419
TTM-5Y1.105-1.105
5Y1.10510Y1.1050.000
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
EOD4.6431.415+3.228
MRQ-1.586-1.586
TTM-2.019-2.019
YOY4.4192.230+2.189
5Y1.1051.895-0.790
10Y1.1051.505-0.400
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Mega Lifesciences Public Company Limited compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.1410.337-142%0.311-145%0.812-117%0.812-117%
Book Value Growth--0.9710.9720%0.9720%0.9720%0.9720%
Book Value Per Share--9.7459.358+4%8.012+22%8.043+21%8.043+21%
Book Value Per Share Growth---0.0150.036-140%0.038-138%0.033-143%0.033-143%
Current Ratio--1.8501.921-4%1.803+3%1.784+4%1.784+4%
Debt To Asset Ratio--0.4130.395+5%0.396+4%0.408+1%0.408+1%
Debt To Equity Ratio--0.7030.655+7%0.662+6%0.695+1%0.695+1%
Dividend Per Share--0.8610.345+149%0.120+619%0.272+216%0.272+216%
Dividend Per Share Growth--0.999-2977.271+298092%-26113.463+2613772%-8739.476+874826%-8739.476+874826%
Eps--0.6530.657-1%0.422+55%0.469+39%0.469+39%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Net Profit Margin--0.1450.153-5%0.108+34%0.122+19%0.122+19%
Operating Margin--0.1530.168-9%0.104+47%0.142+8%0.142+8%
Operating Ratio--1.4241.400+2%1.465-3%1.448-2%1.448-2%
Pb Ratio4.643+100%--0%4.419-100%1.105-100%1.105-100%
Pe Ratio69.273+100%--0%84.752-100%21.188-100%21.188-100%
Price Per Share45.250+100%--0%35.333-100%8.833-100%8.833-100%
Profit Growth--96.90697.3700%97.1600%97.2860%97.2860%
Quick Ratio--0.7550.713+6%0.657+15%0.683+10%0.683+10%
Return On Assets--0.0390.043-8%0.032+24%0.034+16%0.034+16%
Return On Equity--0.0670.071-5%0.053+27%0.057+17%0.057+17%
Revenue Growth--0.9720.9720%0.9730%0.972+0%0.972+0%
Total Gains Per Share--0.7200.682+5%0.431+67%1.084-34%1.084-34%
Total Gains Per Share Growth--0.0510.109-53%-0.229+548%-2.137+4285%-2.137+4285%
Usd Book Value--243848459.400234158959.125+4%200478502.233+22%201248422.783+21%201248422.783+21%
Usd Book Value Change Per Share---0.0040.010-142%0.009-145%0.023-117%0.023-117%
Usd Book Value Per Share--0.2800.269+4%0.230+22%0.231+21%0.231+21%
Usd Dividend Per Share--0.0250.010+149%0.003+619%0.008+216%0.008+216%
Usd Eps--0.0190.019-1%0.012+55%0.013+39%0.013+39%
Usd Price Per Share1.299+100%--0%1.014-100%0.254-100%0.254-100%
Usd Profit--16345023.10016448644.450-1%10550722.700+55%11727621.208+39%11727621.208+39%
Usd Revenue--112786551.500107771563.725+5%97095247.433+16%94288782.058+20%94288782.058+20%
Usd Total Gains Per Share--0.0210.020+5%0.012+67%0.031-34%0.031-34%
 EOD+1 -3MRQTTM+10 -18YOY+23 -95Y+22 -1010Y+22 -10

3.2. Fundamental Score

Let's check the fundamental score of Mega Lifesciences Public Company Limited based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1569.273
Price to Book Ratio (EOD)Between0-14.643
Net Profit Margin (MRQ)Greater than00.145
Operating Margin (MRQ)Greater than00.153
Quick Ratio (MRQ)Greater than10.755
Current Ratio (MRQ)Greater than11.850
Debt to Asset Ratio (MRQ)Less than10.413
Debt to Equity Ratio (MRQ)Less than10.703
Return on Equity (MRQ)Greater than0.150.067
Return on Assets (MRQ)Greater than0.050.039
Total5/10 (50.0%)

3.3. Technical Score

Let's check the technical score of Mega Lifesciences Public Company Limited based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose45.500
Total1/1 (100.0%)



Latest Balance Sheet

Balance Sheet of 2022-06-30. Currency in THB. All numbers in thousands.

Summary
Total Assets14,470,549
Total Liabilities5,974,087
Total Stockholder Equity8,496,324
 As reported
Total Liabilities 5,974,087
Total Stockholder Equity+ 8,496,324
Total Assets = 14,470,549

Assets

Total Assets14,470,549
Total Current Assets10,340,694
Long-term Assets10,340,694
Total Current Assets
Cash And Cash Equivalents 2,119,941
Short-term Investments 335,412
Net Receivables 3,882,582
Inventory 3,864,314
Other Current Assets 138,445
Total Current Assets  (as reported)10,340,694
Total Current Assets  (calculated)10,340,694
+/-0
Long-term Assets
Property Plant Equipment 2,194,061
Goodwill 488,673
Long Term Investments 226,777
Intangible Assets 874,821
Other Assets 345,523
Long-term Assets  (as reported)4,129,855
Long-term Assets  (calculated)4,129,855
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities5,590,429
Long-term Liabilities383,658
Total Stockholder Equity8,496,324
Total Current Liabilities
Short Long Term Debt 187,522
Accounts payable 2,744,970
Other Current Liabilities 1,783,923
Total Current Liabilities  (as reported)5,590,429
Total Current Liabilities  (calculated)4,716,415
+/- 874,014
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt191,643
Other Liabilities 278,194
Long-term Liabilities  (as reported)383,658
Long-term Liabilities  (calculated)469,837
+/- 86,179
Total Stockholder Equity
Common Stock435,935
Retained Earnings 6,213,621
Total Stockholder Equity (as reported)8,496,324
Total Stockholder Equity (calculated)6,649,556
+/- 1,846,768
Other
Capital Stock435,935
Common Stock Shares Outstanding 871,870
Net Invested Capital 8,683,846
Net Tangible Assets 7,132,830
Net Working Capital 4,750,265



Balance Sheet

Currency in THB. All numbers in thousands.

 Trend2022-06-302022-03-312021-12-312021-09-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-30
> Total Assets 
10,092,140
10,191,281
10,532,705
11,189,919
11,325,857
11,693,640
11,589,714
11,430,970
12,548,005
13,271,700
13,639,790
14,470,549
14,470,54913,639,79013,271,70012,548,00511,430,97011,589,71411,693,64011,325,85711,189,91910,532,70510,191,28110,092,140
   > Total Current Assets 
6,956,848
6,974,404
7,245,836
7,230,612
7,318,963
7,603,887
7,619,823
7,380,400
8,568,085
9,300,879
9,620,392
10,340,694
10,340,6949,620,3929,300,8798,568,0857,380,4007,619,8237,603,8877,318,9637,230,6127,245,8366,974,4046,956,848
       Cash And Cash Equivalents 
846,762
1,078,264
1,247,922
998,011
1,038,747
979,423
1,006,451
1,490,461
1,631,935
2,197,692
2,240,723
2,119,941
2,119,9412,240,7232,197,6921,631,9351,490,4611,006,451979,4231,038,747998,0111,247,9221,078,264846,762
       Short-term Investments 
574,473
236,922
207,142
211,091
211,091
211,091
211,091
371,267
333,660
333,660
335,412
335,412
335,412335,412333,660333,660371,267211,091211,091211,091211,091207,142236,922574,473
       Net Receivables 
2,345,270
2,419,472
2,616,400
2,938,159
2,748,106
2,703,804
2,581,435
2,187,762
2,962,725
2,721,433
3,186,344
3,882,582
3,882,5823,186,3442,721,4332,962,7252,187,7622,581,4352,703,8042,748,1062,938,1592,616,4002,419,4722,345,270
       Inventory 
2,730,486
2,791,002
2,855,796
2,793,228
3,143,789
3,544,417
3,474,671
3,044,632
3,424,393
3,822,887
3,727,598
3,864,314
3,864,3143,727,5983,822,8873,424,3933,044,6323,474,6713,544,4173,143,7892,793,2282,855,7962,791,0022,730,486
       Other Current Assets 
16,783
19,730
255,295
290,123
177,230
165,152
287,462
286,278
215,372
162,799
130,315
138,445
138,445130,315162,799215,372286,278287,462165,152177,230290,123255,29519,73016,783
   > Long-term Assets 
3,135,292
3,216,877
3,286,829
3,959,307
4,006,894
4,089,753
3,969,891
4,050,570
3,979,920
3,970,821
4,019,398
4,129,855
4,129,8554,019,3983,970,8213,979,9204,050,5703,969,8914,089,7534,006,8943,959,3073,286,8293,216,8773,135,292
       Property Plant Equipment 
1,635,074
1,693,559
1,770,592
2,222,409
2,194,696
2,307,840
2,213,797
2,236,784
2,081,560
2,102,739
2,174,003
2,194,061
2,194,0612,174,0032,102,7392,081,5602,236,7842,213,7972,307,8402,194,6962,222,4091,770,5921,693,5591,635,074
       Goodwill 
202,332
199,032
199,421
427,829
435,815
442,296
437,318
443,866
481,095
476,253
480,300
488,673
488,673480,300476,253481,095443,866437,318442,296435,815427,829199,421199,032202,332
       Long Term Investments 
248,582
245,226
240,568
258,008
240,521
205,213
194,469
202,617
218,530
214,789
213,941
226,777
226,777213,941214,789218,530202,617194,469205,213240,521258,008240,568245,226248,582
       Intangible Assets 
794,025
791,346
792,128
864,888
861,304
878,093
874,999
883,104
885,722
876,886
868,475
874,821
874,821868,475876,886885,722883,104874,999878,093861,304864,888792,128791,346794,025
       Other Assets 
255,279
287,714
284,120
186,173
274,558
256,311
249,308
284,199
313,013
300,154
282,679
345,523
345,523282,679300,154313,013284,199249,308256,311274,558186,173284,120287,714255,279
> Total Liabilities 
4,272,286
4,395,715
4,357,609
4,932,811
4,819,135
5,037,854
4,610,790
4,109,739
5,053,997
5,246,579
5,019,986
5,974,087
5,974,0875,019,9865,246,5795,053,9974,109,7394,610,7905,037,8544,819,1354,932,8114,357,6094,395,7154,272,286
   > Total Current Liabilities 
4,097,134
4,213,590
4,158,166
4,584,518
4,455,549
4,667,099
4,261,663
3,706,119
4,659,291
4,853,355
4,624,525
5,590,429
5,590,4294,624,5254,853,3554,659,2913,706,1194,261,6634,667,0994,455,5494,584,5184,158,1664,213,5904,097,134
       Short Long Term Debt 
1,226,396
1,165,943
888,306
795,949
1,081,193
796,069
499,491
259,246
156,189
168,176
113,554
187,522
187,522113,554168,176156,189259,246499,491796,0691,081,193795,949888,3061,165,9431,226,396
       Accounts payable 
1,703,818
1,816,502
2,019,591
1,973,590
1,943,201
2,448,183
2,047,757
1,794,744
2,665,863
2,526,618
2,269,949
2,744,970
2,744,9702,269,9492,526,6182,665,8631,794,7442,047,7572,448,1831,943,2011,973,5902,019,5911,816,5021,703,818
       Other Current Liabilities 
0
646,232
334,447
1,183,601
872,432
747,858
849,307
916,068
909,722
818,874
1,442,486
1,783,923
1,783,9231,442,486818,874909,722916,068849,307747,858872,4321,183,601334,447646,2320
   > Long-term Liabilities 
175,152
182,125
199,443
348,293
363,586
370,755
349,127
403,620
394,706
393,224
395,461
383,658
383,658395,461393,224394,706403,620349,127370,755363,586348,293199,443182,125175,152
       Capital Lease Obligations Min Short Term Debt
2,757
2,422
2,170
170,959
172,385
167,586
147,976
210,091
194,457
188,153
184,134
191,643
191,643184,134188,153194,457210,091147,976167,586172,385170,9592,1702,4222,757
       Other Liabilities 
173,626
180,953
198,591
228,665
238,735
247,955
237,819
247,088
258,185
261,281
269,360
278,194
278,194269,360261,281258,185247,088237,819247,955238,735228,665198,591180,953173,626
> Total Stockholder Equity
5,819,748
5,795,471
6,174,998
6,235,502
6,482,492
6,633,448
6,957,637
7,299,783
7,468,950
8,002,820
8,599,557
8,496,324
8,496,3248,599,5578,002,8207,468,9507,299,7836,957,6376,633,4486,482,4926,235,5026,174,9985,795,4715,819,748
   Common Stock
435,935
435,935
435,935
435,935
435,935
435,935
435,935
435,935
435,935
435,935
435,935
435,935
435,935435,935435,935435,935435,935435,935435,935435,935435,935435,935435,935435,935
   Retained Earnings 
3,583,641
3,595,489
4,041,212
3,988,740
4,292,099
4,320,252
4,751,586
5,085,134
5,276,336
5,766,336
6,379,828
6,213,621
6,213,6216,379,8285,766,3365,276,3365,085,1344,751,5864,320,2524,292,0993,988,7404,041,2123,595,4893,583,641
   Accumulated Other Comprehensive Income 000000000000
   Capital Surplus 000000000000
   Treasury Stock000000000000



Balance Sheet

Currency in THB. All numbers in thousands.




Cash Flow

Currency in THB. All numbers in thousands.




Income Statement

Currency in THB. All numbers in thousands.


Latest Income Statement (annual, 2021-12-31)

Gross Profit (+$)
totalRevenue14,135,656
Cost of Revenue-8,224,859
Gross Profit5,910,7975,910,797
 
Operating Income (+$)
Gross Profit5,910,797
Operating Expense-11,994,212
Operating Income2,141,444-6,083,415
 
Operating Expense (+$)
Research Development40,521
Selling General Administrative3,611,607
Selling And Marketing Expenses-
Operating Expense11,994,2123,652,128
 
Net Interest Income (+$)
Interest Income-
Interest Expense-28,275
Net Interest Income-28,275-28,275
 
Pretax Income (+$)
Operating Income2,141,444
Net Interest Income-28,275
Other Non-Operating Income Expenses-
Income Before Tax (EBT)2,276,8811,977,732
EBIT - interestExpense = 2,149,842
2,282,849
1,975,100
Interest Expense28,275
Earnings Before Interest and Taxes (ebit)2,178,1172,305,156
Earnings Before Interest and Taxes (ebitda)2,579,592
 
After tax Income (+$)
Income Before Tax2,276,881
Tax Provision-336,024
Net Income From Continuing Ops1,940,8571,940,857
Net Income1,946,825
Net Income Applicable To Common Shares1,946,825
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net163,71228,275
 

Comments

Join the conversation.

Leave a comment

Stay informed with my latest content.

Subscribe to my newsletter and receive an email as soon as I add content to PenkeTrading.com.


By clicking Register, you agree to the General Terms and Conditions.
Penke's Market Notifications
AMMX.OTCQB
now

I found you a STOCH Bullish Hidden Divergence on the daily chart of AMMX.OTCQB.

AMMX.OTCQB Daily Candlestick Chart
AIMH.PINK
3 minutes ago

I found you a RSI Bearish Reversal Divergence on the daily chart of AIMH.PINK.

AIMH.PINK Daily Candlestick Chart
AERG.OTCQB
6 minutes ago

I found you a Death Cross on the daily chart of AERG.OTCQB.

AERG.OTCQB Daily Candlestick Chart
ADER.NASDAQ
6 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of ADER.NASDAQ.

ADER.NASDAQ Daily Candlestick Chart
ACOG.V
7 minutes ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of ACOG.V.

ACOG.V Daily Candlestick Chart
ACON.NASDAQ
7 minutes ago

I found you a STOCH Bullish Reversal Divergence on the daily chart of ACON.NASDAQ.

ACON.NASDAQ Daily Candlestick Chart
7NR.BSE
10 minutes ago

I found you a RSI Bullish Reversal Divergence on the daily chart of 7NR.BSE.

7NR.BSE Daily Candlestick Chart
6TVL.XETRA
12 minutes ago

I found you a Golden Cross on the daily chart of 6TVL.XETRA.

6TVL.XETRA Daily Candlestick Chart
0RI9.LSE
37 minutes ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of 0RI9.LSE.

0RI9.LSE Daily Candlestick Chart
0QN1.LSE
40 minutes ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of 0QN1.LSE.

0QN1.LSE Daily Candlestick Chart
0NTM.LSE
44 minutes ago

I found you a Golden Cross on the daily chart of 0NTM.LSE.

0NTM.LSE Daily Candlestick Chart
0NOF.LSE
44 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of 0NOF.LSE.

0NOF.LSE Daily Candlestick Chart
0MKW.LSE
46 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of 0MKW.LSE.

0MKW.LSE Daily Candlestick Chart
0H9P.LSE
50 minutes ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of 0H9P.LSE.

0H9P.LSE Daily Candlestick Chart
0DPU.LSE
52 minutes ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of 0DPU.LSE.

0DPU.LSE Daily Candlestick Chart
JJN.NYSE ARC
1 hour ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of JJN.NYSE ARC.

JJN.NYSE ARC Daily Candlestick Chart
JIGB.NYSE ARC
1 hour ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of JIGB.NYSE ARC.

JIGB.NYSE ARC Daily Candlestick Chart
ILTB.NYSE ARC
1 hour ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of ILTB.NYSE ARC.

ILTB.NYSE ARC Daily Candlestick Chart
IHDG.NYSE ARC
1 hour ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of IHDG.NYSE ARC.

IHDG.NYSE ARC Daily Candlestick Chart
IGLB.NYSE ARC
1 hour ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of IGLB.NYSE ARC.

IGLB.NYSE ARC Daily Candlestick Chart
HTRB.NYSE ARC
1 hour ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of HTRB.NYSE ARC.

HTRB.NYSE ARC Daily Candlestick Chart
NMXS.PINK
1 hour ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of NMXS.PINK.

NMXS.PINK Daily Candlestick Chart
HEWJ.NYSE ARC
1 hour ago

I found you a Death Cross on the daily chart of HEWJ.NYSE ARC.

HEWJ.NYSE ARC Daily Candlestick Chart